Table 2 Impact of different definitive regimens on the outcomes among patients with S. maltophilia-HAP via a WPS analysis

30-day mortality

Entire cohort

126/307 (41.0)

1.104 (0.698–1.747)

0.671

1.124 (0.707–1.786)

0.622

Immunocompromised

65/117 (55.6)

0.396 (0.176–0.892)

0.025

0.404 (0.170–0.962)

0.041

Immunocompetent

61/190 (32.1)

1.597 (0.864–2.592)

0.135

1.349 (0.712–2.554)

0.359

APACHE II score ≥ 15

92/193 (47.7)

0.471 (0.256–0.866)

0.015

0.494 (0.256–0.951)

0.035

APACHE II score < 15

34/114 (29.8)

2.956 (1.290–6.770)

0.010

2.357 (0.820–6.677)

0.111

30-day clinical response

Entire cohort

167/307 (54.4)

0.999 (0.636–1.570)

0.996

0.987 (0.626–1.557)

0.956

Immunocompromised

52/117 (44.4)

2.523 (1.121–5.674)

0.025

2.601 (1.088–6.218)

0.032

Immunocompetent

115/190 (60.5)

0.709 (0.395–1.271)

0.248

0.833 (0.453–1.530)

0.555

APACHE II score ≥ 15

95/193 (49.2)

2.128 (1.153–3.926)

0.016

2.096 (1.082–4.058)

0.028

APACHE II score < 15

72/114 (63.2)

0.440 (0.201–0.965)

0.041

0.584 (0.212–1.608)

0.298

30-day microbiology eradiction ǂ

Entire cohort

131/272 (48.2)

1.049 (0.649–1.693)

0.846

1.035 (0.640–1.677)

0.888

Immunocompromised

38/106 (35.8)

2.625 (1.049–6.569)

0.039

2.788 (1.027–7.567)

0.044

Immunocompetent

93/166 (56.0)

0.827 (0.448–1.528)

0.544

0.955 (0.504–1.810)

0.887

APACHE II score ≥ 15

79/175 (45.1)

2.199 (1.150–2.407)

0.017

2.256 (1.123–4.534)

0.022

APACHE II score < 15

52/97 (53.6)

0.388 (0.168–0.896)

0.027

0.478 (0.164–1.397)

0.177